predict

HealthCare AI: The Unavoidable Revolution in Modern Medicine

Source Node:
Time Stamp: October 5, 2023 3:40 PM - Modified On: October 5, 2023 - Published By:
Source Cluster:
Republished By Plato

By Eric Greenberg www.linkedin.com/in/ericabg In the evolving landscape of medical technology, there's one force that stands head and shoulders above the rest, promising a seismic shift in the very ethos of healthcare delivery: Artificial Intelligence (AI). As a seasoned technology and banking analyst, it is my considered opinion that Healthcare AI isn't just a trend or a buzzword. It’s the very future of medicine, poised to reshape everything we know about patient care, disease diagnosis, and medical research. To begin with, the economic implications of integrating AI in healthcare are

Revolutionizing Clinical Trials: The Digital Watermarking and AI Duo

Source Node:
Time Stamp: October 5, 2023 11:22 AM - Modified On: October 5, 2023 - Published By:
Source Cluster:
Republished By Plato

Revolutionizing Clinical Trials: The Digital Watermarking and AI Duo Clinical trials, the linchpin of medical research, have long been riddled with inefficiencies, from patient recruitment bottlenecks to data management hurdles. As a technology and banking analyst, I've seen how digital solutions can overhaul entire sectors, offering improved productivity and streamlined processes. It's high time that clinical trials get a dose of such digital innovation, and there's a potent combination on the horizon: digital watermarking coupled with Artificial Intelligence (AI). At first glance, one might wonder: how can a technique often

The Collision of Titans: AI and Web3

Source Node:
Time Stamp: September 4, 2023 12:28 PM - Modified On: September 4, 2023 - Published By:
Source Cluster:
Republished By Plato

Over the past decade, two titans have emerged from the tech realm, each promising to redefine the very fabric of our global infrastructure - Artificial Intelligence (AI) and Web3. But what happens when these two forces converge? Are we on the brink of a new digital renaissance or a potentially uncharted dystopia? Consider this: AI is, at its core, the embodiment of advanced logic and decision-making, a machine's ability to "think" and process information in ways eerily similar to humans. It's no longer just about algorithms; it's about creating synthetic

Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research

Source Node:
Time Stamp: August 29, 2023 8:20 AM - Modified On: August 29, 2023 - Published By:
Source Cluster:
Republished By Plato

Gain Therapeutics, Inc. (Nasdaq: GANX), a pioneering biotechnology company specializing in innovative allosteric small molecule therapies, has made significant strides in the fight against Parkinson's disease (PD). The Company's lead drug candidate, GT-02287, has demonstrated extraordinary potential in mitigating the effects of Parkinson's disease across two distinct preclinical models of the ailment. These findings suggest that GT-02287 has the capacity to alleviate Parkinson's disease pathology and enhance motor function. A notable highlight is the substantial reduction of plasma Neurofilament Light Chain (NfL) levels, an emerging biomarker for neurodegeneration. This advancement

Livento Group, Inc. Announces Second Quarter Results with Revenue Growth of Over 90%, Including Significant Achievements and Updates

Source Node:
Time Stamp: August 17, 2023 3:06 PM - Modified On: August 17, 2023 - Published By:
Source Cluster:
Republished By Plato

NEW YORK, NY / August 14, 2023 / NuGene International, Inc./Livento Group, Inc. (OTC Pink:NUGN), a dynamic leader specializing in the acquisition and development of companies with disruptive business models in film, content, and technology sectors, is pleased to announce revenue growth of 91.65% for the second quarter of 2023, compared to the same period in 2022. Financial Highlights: Revenue Growth:The second quarter ending June 30, 2023, saw revenues of $431,184, up from $224,986 in 2022. For the six-month period ending June 30, 2023, revenues grew from $680,202 to $922,651, a growth of

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease.

Source Node:
Time Stamp: June 7, 2023 12:22 PM - Modified On: June 7, 2023 - Published By:
Source Cluster:
Republished By Plato

Highlights Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of cognitive decline of the patients over the course of the study. TNF-α is one of the main inflammatory cytokines involved in initiating and propagating

Travelzoo META Opens for Founding Members

Source Node:
Time Stamp: May 11, 2023 7:21 AM - Modified On: May 11, 2023 - Published By:
Source Cluster:
Republished By Plato

NEW YORK/PARIS/TOKYO, May 11, 2023 - (ACN Newswire) - The future of travel is here. After months of anticipation, Travelzoo META, a members-only service offering groundbreaking Metaverse travel experiences, is now accepting its first one million Founding Members. Launched by Travelzoo® (NASDAQ: TZOO), a global Internet media company, Travelzoo META will give Founding Members the opportunity to be the first to experience travel in the Metaverse. Travelzoo META's experiences are intended to allow its members to explore hard-to-reach corners of the world, like summiting Mount Everest, or travel back in time—to

Paribus Mainnet Countdown.

Source Node:
Time Stamp: March 21, 2023 6:32 AM - Modified On: March 21, 2023 - Published By:
Source Cluster:
Republished By Plato

We know the past few months have been drawn out for everyone eagerly awaiting the release date of our mainnet. Throughout each step, we’ve been direct and transparent with our community, and sometimes maybe a little too hopeful. But now the wait is over. Our developers have been working especially hard to meet the exacting requirements of the Hacken audit and we’re over the moon to have achieved a score of 8.7/10 which we feel represents the hard work of everyone involved. Now that we’ve passed with a high score

Paribus: All To Play For.

Source Node:
Time Stamp: March 1, 2023 12:21 AM - Modified On: March 1, 2023 - Published By:
Source Cluster:
Republished By Plato

All To Play For While many people in crypto, especially those on YouTube, focus on technical analysis to predict market trends, we prefer to zoom out and see the broader context. While charts can be helpful, much stronger headwinds often override them. This is especially true when it comes to the present geopolitical situation. Of all the lessons learned in 2022 the most valuable one is that although there are several risk factors inherent to the crypto market itself, it’s also vulnerable to more widespread market moves. Also, due to